Interferon-γ increases monocyte HLA-DR expression without effects on glucose and fat metabolism in postoperative patients

Journal of Applied Physiology

Volumn 96, Issue 2, 2004, Pages 597-603

  De Metz, Jesse ^a   Romijn, Johannes A ^b   Endert, Erik ^a   Ackermans, Mariette T ^a   Jan Weverling, Gerrit ^a   Busch, Olivier R ^a   De Wit, Laurence Th ^a   Gouma, Dirk J ^a   Ten Berge, Ineke J M ^a   Sauerwein, Hans P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Hormones; Human leukocyte antigen; Stable isotopes; Trauma

Indexed keywords

HLA DR ANTIGEN; HUMAN INTERFERON; IMMUKINE; ISOFLURANE; NADROPARIN; OCTREOTIDE; RECOMBINANT GAMMA INTERFERON; SUFENTANIL;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEROL BLOOD LEVEL; HLA SYSTEM; HUMAN; HYPERMETABOLISM; IMMUNE DEFICIENCY; INFLAMMATION; INJURY; LIPID METABOLISM; MAJOR SURGERY; MALE; MONOCYTE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TISSUE INJURY;

AGED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; ENERGY METABOLISM; FEMALE; GLYCEROL; HLA-DR ANTIGENS; HORMONES; HUMANS; INTERFERON TYPE II; LIPID METABOLISM; MALE; MIDDLE AGED; MONOCYTES; POSTOPERATIVE PERIOD;

EID: 0942298583     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00090.2002     Document Type: Article

References (40)

1. Ackermans MT, Ruiter AF, and Endert E. Determination of glycerol concentrations and glycerol isotopic enrichments in human plasma by gas chromatography/mass spectrometry. Anal Biochem 258: 80-86, 1998.
2. Brune IB, Wilke W, Hensler T, Feussner H, Holzmann B, and Siewert JR. Normal T lymphocyte and monocyte function after minimally invasive surgery. Surg Endosc 12: 1020-1024, 1998.
3. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332: 1351-1362, 1995.
4. Corssmit EP, Heijligenberg R, Endert E, Ackermans MT, Sauerwein HP, and Romijn JA. Endocrine and metabolic effects of interferon-alpha in humans. J Clin Endocrinol Metab 81: 3265-3269, 1996.
5. Dahn MS, Lange MP, Mitchell RA, Lobdell K, and Wilson RF. Insulin production following injury and sepsis. J Trauma 27: 1031-1038, 1987.
6. Decker D, Schondorf M, Bidlingmaier F, Hirner A, and von Ruecker AA. Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery 119: 316-325, 1996.
7. De Metz J, Sprangers F, Endert E, Ackermans MT, ten Berge IJM, Sauerwein HP, and Romijn JA. Interferon-γ has immunomodulatory effects with minor endocrine and metabolic effects in humans. J Appl Physiol 86: 517-522, 1999.
8. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, and Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3: 678-681, 1997.
9. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, and Norton JA. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J Immunol 149: 1666-1670, 1992.
10. Dries DJ. Interferon-gamma therapy for infectious complications of injury: a called third strike? Crit Care Med 26: 419-420, 1998.
11. Dries DJ, Jurkovich GJ, Maier RV, Clemmer TP, Struve SN, Weigelt JA, Stanford GG, Herr DL, Champion HR, Lewis FR, et al. Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg 129: 1031-1042, 1994.
12. Feingold KR, Doerrler W, Dinarello CA, Fiers W, and Grunfeld C. Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 130: 10-16, 1992.
13. Gelfand RA, Matthews DE, Bier DM, and Sherwin RS. Role of counterregulatory hormones in the catabolic response to stress. J Clin Invest 74: 2238-2248, 1984.
14. Goldstein D, Gockerman J, Krishnan R, Ritchie J Jr, Tso CY, Hood LE, Ellinwood E and Laszlo J. Effects of gamma-interferon on the endocrine system: results from a phase I study. Cancer Res 47: 6397-6401, 1987.
15. Haupt W, Riese J, Mehler C, Weber K, Zowe M, and Hohenberger W. Monocyte function before and after surgical trauma. Dig Surg 15: 102-104, 1998.
16. Hensler T, Hecker H, Heeg K, Heidecke CD, Bartels H, Barthlen W, Wagner H, Siewert JR, and Holzmann B. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 65: 2283-2291, 1997.
17. Hershman MJ, Appel SH, Wellhausen SR, Sonnenfeld G, and Polk HC Jr. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 77: 67-70, 1989.
18. Hershman MJ, Cheadle WG, Wellhausen SR, Davidson PF, and Polk HC Jr. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 77: 204-207, 1990.
19. Holsboer F, Stalla GK, von Bardeleben U, Hammann K, Muller H, and Muller OA. Acute adrenocortical stimulation by recombinant gamma interferon in human controls. Life Sci 42: 1-5, 1988.
20. Klava A, Windsor A, Boylston AW, Reynolds JV, Ramsden CW, and Guillou PJ. Monocyte activation after open and laparoscopic surgery. Br J Surg 84: 1152-1156, 1997.
21. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, and Volk HD. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 157: 389-393, 1997.
22. Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G, and Polk HC Jr. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 123: 1309-1312, 1988.
23. Livingston DH, Loder PA, Kramer SM, Gibson UE, and Polk HC Jr. Interferon gamma administration increases monocyte HLA-DR antigen expression but not endogenous interferon production. Arch Surg 129: 172-178, 1994.
24. Mack VE, McCarter MD, Naama HA, Calvano SE, and Daly JM. Dominance of T-helper 2-type cytokines after severe injury. Arch Surg 131: 1303-1308, 1996.
25. Mock CN, Dries DJ, Jurkovich GJ, and Maier RV. Assessment of two clinical trials: interferon-gamma therapy in severe injury. Shock 5: 235-240, 1996.
26. Nelson KM, Long CL, Bailey R, Smith RJ, Laws HL, and Blakemore WS. Regulation of glucose kinetics in trauma patients by insulin and glucagon. Metabolism 41: 68-75, 1992.
27. Okusawa S, Dinarello CA, Yancey KB, Endres S, Lawley TJ, Frank MM, Burke JF, and Gelfand JA. C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma. J Immunol 139: 2635-2640, 1987.
28. Polk HC Jr, Cheadle WG, Livingston DH, Rodriguez JL, Starko KM, Izu, AE, Jaffe HS, and Sonnenfeld G. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 163: 191-196, 1992.
29. Reinauer H, Gries FA, Hubinger A, Knode O, Severing K, and Susanto F. Determination of glucose turnover and glucose oxidation rates in man with stable isotope tracers. J Clin Chem Clin Biochem 28: 505-511, 1990.
30. Shamoon H, Hendler R, and Sherwin RS. Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab 52: 1235-1241, 1981.
31. Smedes F, Kraak JC, and Poppe H. Simple and fast solvent extraction system for selective and quantitative isolation of adrenaline, noradrenaline and dopamine from plasma and urine. J Chromatogr 231: 25-39, 1982.
32. Spath-Schwalbe E, Porzsolt F, Digel W, Born J, Kloss B, and Fehm HL. Elevated plasma cortisol levels during interferon-gamma treatment. Immunopharmacology 17: 141-145, 1989.
33. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, and Sauerwein HP. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268: E813-E819, 1995.
34. Tengku-Muhammad TS, Hughes TR, Cryer A, and Ramji DP. Synergism between lipopolysaccharide and interferon gamma in the regulation of lipoprotein lipase in macrophages. Cytokine 11: 408-415, 1999.
35. Van der Hoorn FA, Boomsma F, Man in 't Veld AJ, and Schalekamp MA. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr 487: 17-28, 1989.
36. Van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, and Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol Endocrinol Metab 261: E457-E465, 1991.
37. Wakefield CH, Carey PD, Foulds S, Monson JR, and Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 80: 205-209, 1993.
38. Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G, and Steinmann GG. Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit Care Med 26: 434-439, 1998.
39. Watters J and Wilmore D. The metabolic response to trauma and sepsis. In: Endocrinology, edited by DeGroot LJ. Philadelphia, PA: Saunders, 1989, p. 2367-2393.
40. Wiesenfeld M, O'Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons RJ Jr, Krook JE, Mailliard JA, Gerstner JB, and Pazdur R. Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 13: 2324-2329, 1995.